TEVA
HEALTHCARETeva- Pharmaceutical Industries Ltd
AI Insight
What's Moving TEVA Today?
No stock-specific AI insight has been generated for TEVA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$14.99$37.35
$33.21
Fundamentals
Market Cap$37.5B
P/E Ratio24.0
EPS$1.34
Dividend Yield—
Dividend / Share—
ROE21.6%
Profit Margin9.0%
Debt / Equity—
Trading
Volume5.6M
Avg Volume (10D)—
Shares Outstanding1.16B
TEVA News
41 articles- Is Ecopipam’s FDA Filing Reshaping the Investment Case For Teva Pharmaceutical Industries (TEVA)?Yahoo Finance·Jun 23, 2026
- Merck's Anti-TL1A Antibody Meets Goal in Ulcerative Colitis StudyYahoo Finance·Jun 23, 2026
- Teva's Shift Beyond Generics Puts Focus on Branded Drug GrowthYahoo Finance·Jun 23, 2026
- Teva (NYSE: TEVA) EVP sells 9,989 ordinary shares in open tradeStock Titan·Jun 23, 2026
- New Austedo Data Gives Teva (TEVA) Another Reason for OptimismYahoo Finance·Jun 22, 2026
- Teva Seeks FDA Nod for Ecopipam in Pediatric Tourette SyndromeYahoo Finance·Jun 19, 2026
- Teva Just Delivered More Good News on Its Biggest Growth Driver. Is the Stock Still a Bargain?Motley Fool·Jun 19, 2026
- J&J Stock Down 3% in 3 Months: Is the Dip a Buying Opportunity?Yahoo Finance·Jun 19, 2026
- Teva Pharmaceutical Industries LtdVia Ritzau·Jun 19, 2026
- FDA Seeks Updated Labeling for Testosterone TherapiesYahoo Finance·Jun 18, 2026
- Teva Releases Q2 2026 Aide MemoireYahoo Finance·Jun 18, 2026
- Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette SyndromeYahoo Finance·Jun 18, 2026
- Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ETYahoo Finance·Jun 18, 2026
- Vedana debuts with $46m to progress migraine therapiesPharmaceutical-technology·Jun 17, 2026
- Medincell SA (STU:MEB) Full Year 2026 Earnings Call Highlights: Strategic Growth and ChallengesYahoo Finance·Jun 17, 2026
- Medincell Reports FY 2025-26 Annual ResultsYahoo Finance·Jun 16, 2026
- Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares?The Motley Fool·Jun 14, 2026
- Teva Refocuses On Higher‑Margin Drugs With Emalex Deal And API CutsYahoo Finance·Jun 13, 2026
- Teva's Biosimilar Boom Is Just Getting Started. Is It Time to Buy This Rebounding Pharma Stock?Motley Fool·Jun 12, 2026
- Paragon Advances Registration-Ready CNS Asset Addressing Important Unmet Need and Closes Sale to Teva PharmaceuticalYahoo Finance·Jun 11, 2026
- How Investors Are Reacting To Teva (TEVA) AUSTEDO Real‑World Data On Tardive Dyskinesia ImprovementSimply Wall Street·Jun 10, 2026
- Alvotech Hits Critical Inflection as Biosimilar Pipeline Nears FDA DecisionsMarketbeat·Jun 10, 2026
- Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth StrategyYahoo Finance·Jun 10, 2026
- Is Amneal a Buy Before Rytary Generic Erosion?Yahoo Finance·Jun 9, 2026
- TD Asset Management Inc Purchases 118,075 Shares of Teva Pharmaceutical Industries Ltd. $TEVAMarketBeat·Jun 9, 2026
- [Latest] Global Generic Drug Market Size/Share Worth USD 926.54 Billion by 2034 at a 6.55% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)GlobeNewswire Inc.·Jun 9, 2026
- Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by BNP Paribas Financial MarketsMarketBeat·Jun 7, 2026
- Arrowpoint Investment Partners Singapore Pte. Ltd. Acquires Shares of 152,712 Teva Pharmaceutical Industries Ltd. $TEVAMarketBeat·Jun 5, 2026
- UroGen Pharma, Teva End Patent Dispute Over Urinary Cancer DrugBloomberg Law News·Jun 4, 2026
- $35M QVAR antitrust class action settlementClass Action Lawsuits·Jun 2, 2026
- A Look At Teva (NYSE:TEVA) Valuation After EMA Accepts Filing For Monthly Schizophrenia InjectionSimply Wall Street·May 24, 2026
- Swiss Life Asset Management Ltd Lowers Position in Teva Pharmaceutical Industries Ltd. $TEVAMarketBeat·May 15, 2026
- Dermatomycoses Market Report 2025-2035, Profiles of Prominent Players - Kaken Pharma, Novartis, Glenmark Pharma, Sun Pharma, Teva Pharmaceutical, Bayer, and GaldermaGlobeNewswire Inc.·Apr 23, 2026
- Biolojic Design Presents New Preclinical Data for BD200, a First-in-Class Multibody-Drug Conjugate Targeting Trop-2 and Nectin-4 at the American Association of Cancer Research Annual MeetingGlobeNewswire Inc.·Apr 17, 2026
- Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care PartnersGlobeNewswire Inc.·Apr 15, 2026
- Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable ClinicsGlobeNewswire Inc.·Apr 14, 2026
- Crohn's Disease Eight-Market Drug Forecast and Market Analysis Report 2025-2026: Novel MOAs Will Provide Market Shifts Throughout the Forecast Period to 2032GlobeNewswire Inc.·Apr 10, 2026
- Viatris at $14: A Double-Digit FCF Yield Hiding in Plain SightInvesting.com·Apr 2, 2026
- Teva gewinnt an Dynamik im Biosimilar-Geschäft mit der FDA-Zulassung für PONLIMSI™ (Denosumab-adet) und der Annahme von parallelen Zulassungsanträgen für einen Biosimilar-Kandidaten zu Xolair® (Omalizumab)GlobeNewswire Inc.·Mar 30, 2026
- Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)GlobeNewswire Inc.·Mar 30, 2026
Price Data
Open$32.14
Previous Close$32.20
Day High$33.34
Day Low$32.12
52 Week High$37.35
52 Week Low$14.99
52-Week Range
$14.99$37.35
$33.21
Fundamentals
Market Cap$37.5B
P/E Ratio24.0
EPS$1.34
Dividend Yield—
Dividend / Share—
ROE21.6%
Profit Margin9.0%
Debt / Equity—
Trading
Volume5.6M
Avg Volume (10D)—
Shares Outstanding1.16B
About Teva- Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Company Details
Security TypeStock
ExchangeNYSE
CurrencyUSD
Round Lot—
SICDRUG MANUFACTURERS - SPECIALTY & GENERIC
CIK—
Composite FIGI—
Share Class FIGI—